$CLBT

Jewell Marcus sold $141K of CLBT

Jewell Marcus (Global Chief Revenue Officer) sold 12,562 shares of Cellebrite DI Ltd. (CLBT) at $11.24 ($0.14M total) on 2026-08-21.

Original reporting
SEC EDGAR · Jewell Marcus
Published Aug 24, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The CRO's sale represents a routine liquidity event; unlikely to move the stock significantly.

02

Market read

Minor insider sell with limited impact on price or sector.

03

What to watch

Potential upcoming product announcements or contract wins could offset any negative sentiment.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; investors monitor sales by senior executives for signals.

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

Cellebrite CRO Jewell Marcus sold 12,562 shares for $141,216, a Form 4 insider sale disclosed on 2026-08-24.

Expected impact

Potential slight downward pressure, likely negligible.

Evidence & confidence

Sale size is small relative to holdings and market cap; no broader implications.

Market effects

None; insider sale does not affect the broader digital forensics sector.

None; limited to Cellebrite shareholders.

Minimal; no macro or sector-wide effect.

Counterpoint

The sale could signal insider concern, but size is too small to infer material risk.

Key entities

  • Cellebrite DI Ltd.

    Provider of digital intelligence solutions, ticker CLBT.

  • Jewell Marcus

    Global Chief Revenue Officer of Cellebrite.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.